keyword
MENU ▼
Read by QxMD icon Read
search

metformin and weight loss

keyword
https://www.readbyqxmd.com/read/29344336/treating-nonalcoholic-fatty-liver-disease-in-patients-with-type-2-diabetes-mellitus-a-review-of-efficacy-and-safety
#1
REVIEW
Elizabeth P Mills, K Paige D Brown, Jennifer D Smith, Phillip W Vang, Katie Trotta
Objective: To review current literature for the efficacy and safety of treatment for nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Data sources: A PubMed literature search from January 1990 to June 2017 was conducted using the search terms nonalcoholic fatty liver disease, diabetes mellitus, type 2, therapy, treatment, treat, therapeutics, nonalcoholic fatty liver, nonalcoholic hepatosteatosis, NASH, NAFLD, metformin, and statin...
January 2018: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29338714/the-effects-of-metformin-in-type-1-diabetes-mellitus
#2
Selvihan Beysel, Ilknur Ozturk Unsal, Muhammed Kizilgul, Mustafa Caliskan, Bekir Ucan, Erman Cakal
BACKGROUND: This retrospective study investigated the effect of adding metformin to pharmacologic insulin dosing in type 1 diabetics on insulin therapy 1 year after treatment compared with patients on insulin therapy alone. METHODS: Twenty-nine adults with type 1 diabetes who had metformin added to their insulin therapy for 12 months were compared with 29 adults with type 1 diabetes who remained on insulin-alone therapy. RESULTS: Fifty-eight patients with C peptide negative-type 1 diabetics (26 females, mean age: 29...
January 16, 2018: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/29320602/when-metformin-is-not-enough-pros-and-cons-of-sglt2-and-dpp-4-inhibitors-as-a-second-line-therapy
#3
REVIEW
Angelo Avogaro, Elías Delgado, Ildiko Lingvay
The newer oral therapies for type 2 diabetes (T2DM); dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors have advantages over older agents. DPP-4 inhibitors are weight neutral, and have few adverse effects. SGLT2 inhibitors have additional benefits; weight loss, blood pressure reduction, cardiovascular risk reduction, and renoprotective effects. SGLT2 inhibitors, have increased risk of urogenital infections and possible risk of "euglycaemic" diabetic ketoacidosis...
January 10, 2018: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/29316164/effects-of-exenatide-once-weekly-plus-dapagliflozin-exenatide-once-weekly-or-dapagliflozin-added-to-metformin-monotherapy-on-body-weight-systolic-blood-pressure-and-triglycerides-in-patients-with-type-2-diabetes-in-the-duration-8-study
#4
Serge A Jabbour, Juan P Frías, Cristian Guja, Elise Hardy, Azazuddin Ahmed, Peter Öhman
This post hoc analysis assessed the effects on cardiovascular risk factors of body weight, systolic blood pressure (SBP), and triglycerides after 28 weeks' treatment with exenatide once weekly (QW) plus dapagliflozin, as compared with exenatide QW or dapagliflozin, in patient subpopulations from the DURATION-8 trial of patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone. Subgroups of patients were stratified according to their baseline body weight, SBP, and triglycerides...
January 5, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29304290/effects-of-metformin-on-insulin-resistance-and-metabolic-disorders-in-tumor-bearing-rats-with-advanced-cachexia
#5
Flaviane de Fatima Silva, Milene Ortiz-Silva, Winny Beatriz de Souza Galia, Priscila Cassolla, Francemilson Goulart da Silva, Maria Fernanda Rodrigues Graciano, Angelo Carpinelli, Helenir Medri de Souza
Metformin (MET) is widely used in the correction of insulin (INS) resistance and metabolic abnormalities in type 2 diabetes. However, its effect on INS resistance and metabolic disorders associated with cancer cachexia is not established. We investigated the MET effects, isolated or associated with INS, on INS resistance and metabolic changes induced by Walker-256 tumor in rats with advanced cachexia. MET (500 mg.kg-1, oral) and MET + INS (NPH, 1.0 IU.kg-1, sc) were administered during 12 days, starting on the day of tumor cell inoculation...
January 5, 2018: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/29235180/the-effects-of-hypoglycemia-and-weight-loss-of-total-lignans-from-fructus-arctii-in-kkay-mice-and-its-mechanisms-of-the-activity
#6
Yingying Gao, Chenchen Gu, Kai Wang, Haiying Wang, Kefeng Ruan, Zhaohui Xu, Yi Feng
Fructus Arctii (great burdock achene) is the dried ripe fruit of Arctium lappa L. (family Asteraceae) and is included in the Chinese pharmacopoeia. It has been reported that the clinical use of Fructus Arctii resulted in a satisfactory hypoglycemic effect in diabetic patients. This study aimed to investigate antidiabetic activity and mechanism of total lignans from Fructus Arctii (TLFA) in KKAy mice, a spontaneous Type 2 diabetic rodent model that exhibits marked obesity. In this study, KKAy mice were gavaged once daily with solvents (0...
December 13, 2017: Phytotherapy Research: PTR
https://www.readbyqxmd.com/read/29217653/exenatide-treatment-causes-suppression-of-serum-fasting-ghrelin-levels-in-patients-with-type-2-diabetes-mellitus
#7
Metin Guclu, Sinem Kiyici, Zulfiye Gul, Sinan Cavun
AIM: In the present study we investigated the long-term effects of exenatide treatment on serum fasting ghrelin levels in patients with type 2 diabetes mellitus. METHODS: Type 2 diabetic patients, who were using metformin with and without the other antihiperglycemic drugs on a stable dose for at least 3 months, were enrolled in the study. BMI>35 kg/m2 and HbA1c>7.0% were the additional inclusion criteria. Oral antihyperglycemic drugs, other than metformin, were stopped and metformin treatment was continued at 2000 mg per day...
December 7, 2017: Endocrine Connections
https://www.readbyqxmd.com/read/29215299/complex-assessment-of-metabolic-effectiveness-of-insulin-pump-therapy-in-patients-with-type-2-diabetes-beyond-hba1c-reduction
#8
Rudolf Chlup, Sarah Runzis, Javier Castaneda, Scott W Lee, Xuan Nguyen, Ohad Cohen
BACKGROUND: This prospective single-center study recruited insulin-resistant continuous subcutaneous insulin infusion (CSII) therapy-naive patients with type 2 diabetes (T2D) using insulin analog-based multiple daily injections (MDI) therapy and metformin. METHODS: A total of 23 individuals with T2D (70% male), aged a mean ± standard deviation 57.2 ± 8.03 years, with body mass index of 36.2 ± 7.02 kg/m2, diabetes duration of 13.3 ± 4.64 years, and HbA1c of 10...
December 7, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/29199483/anthropometric-and-metabolic-improvements-in-human-type-2-diabetes-after-introduction-of-an-okinawan-based-nordic-diet-are-not-associated-with-changes-in-microbial-diversity-or-scfa-concentrations
#9
Fang Huang, Clara Nilholm, Bodil Roth, Caroline Linninge, Peter Höglund, Margareta Nyman, Bodil Ohlsson
The Okinawan-based Nordic (O-BN) diet improves anthropometry and metabolism in type 2 diabetes mellitus (T2DM) patients. The aim of this study was to study mechanisms behind improvements by examining Enterobacteriaceae abundance, microbial diversity, and concentrations of short-chain fatty acids (SCFAs). A secondary aim was exploring if metformin treatment affects microbiota or SCFAs. Thirty T2DM patients received the O-BN diet for 12 weeks. Faecal and blood samples were collected at baseline, 12 and 28 weeks...
December 4, 2017: International Journal of Food Sciences and Nutrition
https://www.readbyqxmd.com/read/29164116/potential-of-metformin-to-improve-cardiac-risk-in-postpartum-women-with-gestational-diabetes
#10
Oscar A Viteri, Mary Alice Sallman, Pauline M Berens, Pamela D Berens, Farah H Amro, Maria S Hutchinson, Susan M Ramin, Sean C Blackwell, Jerrie S Refuerzo, Judith A Smith
Objective: Pregnancy is associated with an increase in total cholesterol, high density lipoproteins (HDL), and low-density lipoproteins (LDL). Postpartum, HDL and LDL decrease over the first 12 weeks postpartum. Oxidized LDL (ox-LDL) is a marker of oxidative stress-related inflammation, which is associated with obesity and also with development of cardiovascular disease. Cardiovascular protection and weight loss are benefits from metformin, especially in women with diabetes. The objective of this study was to compare changes in lipid profiles and biomarkers for obesity during the initial 6 weeks postpartum between women with gestational diabetes mellitus (GDM) treated with metformin versus placebo...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/29158709/relationship-between-health-literacy-and-body-mass-index-among-arab-women-with-polycystic-ovary-syndrome
#11
Yazed Sulaiman Al-Ruthia, Bander Balkhi, Sultan AlGhadeer, Wael Mansy, Hisham AlSanawi, Reem AlGasem, Lama AlMutairi, Ibrahim Sales
Background: Polycystic ovary syndrome (PCOS) puts patients at higher risk for obesity and diabetes. Poor health literacy is also associated with these conditions. Notably, weight loss is associated with improved ovulation and pregnancy rates for women with PCOS. In this study the association between health literacy and body mass index (BMI) among women with PCOS was examined. Methods: The health literacy of women with PCOS was measured using the Arabic version of the single item literacy screener (SILS) at a university medical center...
November 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/29143783/metformin-potentiates-the-benefits-of-dietary-restraint-a-metabolomic-study
#12
Marta Riera-Borrull, Anabel García-Heredia, Salvador Fernández-Arroyo, Anna Hernández-Aguilera, Noemí Cabré, Elisabet Cuyàs, Fedra Luciano-Mateo, Jordi Camps, Javier A Menendez, Jorge Joven
Prevention of the metabolic consequences of a chronic energy-dense/high-fat diet (HFD) represents a public health priority. Metformin is a strong candidate to be incorporated in alternative therapeutic approaches. We used a targeted metabolomic approach to assess changes related to the multi-faceted metabolic disturbances provoked by HFD. We evaluated the protective effects of metformin and explored how pro-inflammatory and metabolic changes respond when mice rendered obese, glucose-intolerant and hyperlipidemic were switched to diet reversal with or without metformin...
October 28, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29064743/dipeptidyl-peptidase-4-inhibitor-sitagliptin-prevented-weight-regain-in-obese-women-with-polycystic-ovary-syndrome-previously-treated-with-liraglutide-a-pilot-randomized-study
#13
Simona Ferjan, Andrej Janez, Mojca Jensterle
BACKGROUND: Weight loss is often nonsustainable after liraglutide cessation. The present study is the first insight into the potential prevention of weight regain in obese subjects who have been withdrawn from liraglutide. We evaluated whether dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin in adjunct to metformin prevents body weight regain more effectively than metformin alone in obese polycystic ovary syndrome (PCOS) previously treated with liraglutide. METHODS: A 12-week prospective randomized open-label study was conducted with 24 obese women with PCOS who had been pretreated with liraglutide 3...
October 24, 2017: Metabolic Syndrome and related Disorders
https://www.readbyqxmd.com/read/29058235/risk-of-metformin-associated-lactic-acidosis-mala-in-patients-after-gastric-bypass-surgery
#14
Laura N Deden, Edo O Aarts, Stephanie C W Aelfers, Marcel M G J van Borren, Ignace M C Janssen, Frits J Berends, Hans de Boer
BACKGROUND: Pharmacokinetic data suggest that the risk of metformin-associated lactic acidosis (MALA) may be increased after Roux-en-Y gastric bypass (RYGB) surgery. The aim of this study was to examine the impact of metformin on plasma lactate levels before and after RYGB surgery. METHODS: Retrospective study of plasma lactate levels before and 3 months after RYGB surgery in patients with type 2 diabetes mellitus (T2DM) not using metformin (MET-0, N = 58), on a stable dose (MET-S, N = 138), or on a decreasing dose (MET-D, N = 85) of metformin...
October 23, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28954840/a-high-carbohydrate-high-fiber-low-fat-diet-results-in-weight-loss-among-adults-at-high-risk-of-type-2-diabetes
#15
RANDOMIZED CONTROLLED TRIAL
Allison C Sylvetsky, Sharon L Edelstein, Geoffrey Walford, Edward J Boyko, Edward S Horton, Uzoma N Ibebuogu, William C Knowler, Maria G Montez, Marinella Temprosa, Mary Hoskin, Kristina I Rother, Linda M Delahanty
Background: Weight loss is a key factor in reducing diabetes risk. The Diabetes Prevention Program (DPP) is a completed clinical trial that randomly assigned individuals at high risk of diabetes to a placebo (PLBO), metformin (MET), or intensive lifestyle intervention (ILS) group, which included physical activity (PA) and reduced dietary fat intake.Objective: We aimed to evaluate the associations between diet and weight at baseline and to identify specific dietary factors that predicted weight loss among DPP participants...
November 2017: Journal of Nutrition
https://www.readbyqxmd.com/read/28953663/efficacy-and-safety-of-liraglutide-versus-sitagliptin-both-in-combination-with-metformin-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#16
REVIEW
Mingxing Li, Yi Yang, Deqi Jiang, Miaofa Ying, Yong Wang, Rui Zhao
BACKGROUND: The aim of this systematic review was to evaluate the efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes and provide reference basis for rational use of clinical drugs. METHODS: Several databases were searched, including Web of science, PubMed, Cochrane library, CNKI, and Wanfang database. Only randomized controlled trials (RCTs) of liraglutide versus sitagliptin both in combination with metformin up to 31 August 2016 were included...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28942807/a-randomized-placebo-controlled-trial-of-metformin-for-the-treatment-of-overweight-induced-by-antipsychotic-medication-in-young-people-with-autism-spectrum-disorder-open-label-extension
#17
Benjamin L Handen, Evdokia Anagnostou, Michael G Aman, Kevin B Sanders, James Chan, Jill A Hollway, Jessica Brian, L Eugene Arnold, Lucia Capano, Craig Williams, Jessica A Hellings, Eric Butter, Deepali Mankad, Rameshwari Tumuluru, Jessica Kettel, Cassandra R Newsom, Naomi Peleg, Dina Odrobina, Sarah McAuliffe-Bellin, Sarah Marler, Taylor Wong, Alexis Wagner, Stasia Hadjiyannakis, Eric A Macklin, Jeremy Veenstra-VanderWeele
OBJECTIVE: A previous study reported on a 16-week placebo-controlled, randomized clinical trial (RCT) of metformin for weight stabilization in 61 children and adolescents 6 to 17 years old with autism spectrum disorder who were prescribed atypical antipsychotics. The present study describes the results of a 16-week open-label extension. METHOD: Fifty-two participants from the acute trial (85%) entered the extension; 22 had been on metformin during the initial RCT and 30 had been on placebo...
October 2017: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/28912879/a-crossover-study-of-the-combination-therapy-of-metformin-and-exenatide-or-biphasic-insulin-aspart-30-in-overweight-or-obese-patients-newly-diagnosed-with-type-2-diabetes-mellitus
#18
Huibiao Quan, Huachuan Zhang, Weiping Wei, Tuanyu Fang, Daoxiong Chen, Kaining Chen
The aim of the present study was to explore the effects of various combinations of exenatide, metformin (MET) and biphasic insulin aspart 30 (BIA30) on type 2 diabetes mellitus (T2DM). Two hundred overweight or obese patients newly diagnosed with T2DM were evenly randomized into two groups: A (twice daily for all: Phase I, 5 µg exenatide + 0.5 g MET for 4 weeks, then 10 µg exenatide + 0.5 g MET for 8 weeks; Phase II, 0.5 g MET for 12 weeks; Phase III, 0.3-0.4 U/kg/day BIA30 + 0.5 g MET for 12 weeks) and B (Phases I, II, III matched the phases III, II and I in group A)...
October 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28912305/effects-of-liraglutide-on-weight-loss-fat-distribution-and-%C3%AE-cell-function-in-obese-subjects-with-prediabetes-or-early-type-2-diabetes
#19
Francesca Santilli, Paola G Simeone, Maria T Guagnano, Marika Leo, Marica T Maccarone, Augusto Di Castelnuovo, Cristina Sborgia, Riccardo C Bonadonna, Ermanno Angelucci, Virginia Federico, Stefano Cianfarani, Lamberto Manzoli, Giovanni Davì, Armando Tartaro, Agostino Consoli
OBJECTIVE: Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We determined whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes...
November 2017: Diabetes Care
https://www.readbyqxmd.com/read/28898436/letter-to-liu-et-al-s-efficacy-of-exenatide-on-weight-loss-metabolic-parameters-and-pregnancy-in-overweight-obese-polycystic-ovary-syndrome
#20
LETTER
Richard S Legro
No abstract text is available yet for this article.
September 12, 2017: Clinical Endocrinology
keyword
keyword
99421
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"